HK1217019A1 - 作爲鹽皮質激素受體拮抗劑的化合物的晶型及其製備方法 - Google Patents
作爲鹽皮質激素受體拮抗劑的化合物的晶型及其製備方法Info
- Publication number
- HK1217019A1 HK1217019A1 HK16105012.5A HK16105012A HK1217019A1 HK 1217019 A1 HK1217019 A1 HK 1217019A1 HK 16105012 A HK16105012 A HK 16105012A HK 1217019 A1 HK1217019 A1 HK 1217019A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- preparation
- receptor antagonist
- compound used
- crystal form
- method therefor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210563636 | 2012-12-22 | ||
PCT/CN2013/090252 WO2014094664A1 (zh) | 2012-12-22 | 2013-12-23 | 作为盐皮质激素受体拮抗剂的化合物的晶型及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1217019A1 true HK1217019A1 (zh) | 2016-12-16 |
Family
ID=50977609
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16100440.8A HK1212676A1 (zh) | 2012-12-22 | 2016-01-15 | 作爲鹽皮質激素受體拮抗劑的化合物的晶型及其製備方法 |
HK16105012.5A HK1217019A1 (zh) | 2012-12-22 | 2016-05-03 | 作爲鹽皮質激素受體拮抗劑的化合物的晶型及其製備方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16100440.8A HK1212676A1 (zh) | 2012-12-22 | 2016-01-15 | 作爲鹽皮質激素受體拮抗劑的化合物的晶型及其製備方法 |
Country Status (17)
Country | Link |
---|---|
US (1) | US9809589B2 (zh) |
EP (2) | EP3954688A1 (zh) |
JP (6) | JP2016503041A (zh) |
KR (1) | KR101737883B1 (zh) |
CN (1) | CN105026391B (zh) |
AU (1) | AU2013362400B2 (zh) |
BR (1) | BR112015014839B1 (zh) |
CA (1) | CA2895968C (zh) |
ES (1) | ES2897496T3 (zh) |
HK (2) | HK1212676A1 (zh) |
IL (1) | IL239581B (zh) |
MX (1) | MX360889B (zh) |
NZ (1) | NZ709361A (zh) |
RU (1) | RU2622105C2 (zh) |
SG (1) | SG11201504928XA (zh) |
WO (1) | WO2014094664A1 (zh) |
ZA (1) | ZA201504485B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9809589B2 (en) * | 2012-12-22 | 2017-11-07 | Kbp Biosciences Co., Ltd. | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor |
CN109069502B (zh) * | 2016-09-24 | 2021-08-06 | 山东亨利医药科技有限责任公司 | 含盐皮质激素受体拮抗剂的药物组合物及其用途 |
JP7291426B2 (ja) * | 2019-03-01 | 2023-06-15 | 山東亨利醫藥科技有限責任公司 | 縮合三環式化合物を調製するための方法、及びその中間体 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5245716B1 (zh) * | 1970-07-10 | 1977-11-17 | ||
CN85101404A (zh) * | 1985-05-16 | 1987-01-17 | 帝人株式会社 | 头孢菌素衍生物的生产过程 |
JPH04235188A (ja) * | 1990-06-19 | 1992-08-24 | Takeda Chem Ind Ltd | ペネム化合物の結晶、その製造方法および抗菌剤 |
DE4235133A1 (de) * | 1992-10-19 | 1994-04-21 | Bayer Ag | Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid |
JP3623531B2 (ja) * | 1993-06-07 | 2005-02-23 | ビーエーエスエフ アクチェンゲゼルシャフト | 結晶質l−アスコルビン酸−2−燐酸エステルマグネシウム塩の製造法 |
WO1998000969A1 (en) * | 1996-06-28 | 1998-01-08 | Philips Electronics N.V. | Method and arrangement for transmitting teletext pages |
WO1998009969A1 (en) * | 1996-09-05 | 1998-03-12 | Astra Pharmaceuticals Ltd. | Novel aryl-pyridazines |
US7081456B2 (en) * | 2002-11-22 | 2006-07-25 | Active Biotech Ab | Immunomodulatory compounds |
CN101103025B (zh) * | 2005-03-21 | 2010-09-08 | 卫材R&D管理有限公司 | 5-[2-氨基-4-(2-呋喃基)嘧啶-5-基]-1-甲基吡啶-2(1h)-酮的结晶及其制备方法 |
DE102007054497B3 (de) * | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
CN102372710A (zh) | 2010-08-18 | 2012-03-14 | 山东轩竹医药科技有限公司 | 作为盐皮质激素受体拮抗剂的并环类化合物 |
PL2623498T3 (pl) * | 2010-09-30 | 2016-05-31 | Toyama Chemical Co Ltd | Sól sodowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu |
US9809589B2 (en) * | 2012-12-22 | 2017-11-07 | Kbp Biosciences Co., Ltd. | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor |
-
2013
- 2013-12-23 US US14/653,933 patent/US9809589B2/en active Active
- 2013-12-23 KR KR1020157019924A patent/KR101737883B1/ko active IP Right Grant
- 2013-12-23 AU AU2013362400A patent/AU2013362400B2/en active Active
- 2013-12-23 SG SG11201504928XA patent/SG11201504928XA/en unknown
- 2013-12-23 MX MX2015008193A patent/MX360889B/es active IP Right Grant
- 2013-12-23 NZ NZ709361A patent/NZ709361A/en unknown
- 2013-12-23 JP JP2015548180A patent/JP2016503041A/ja active Pending
- 2013-12-23 CA CA2895968A patent/CA2895968C/en active Active
- 2013-12-23 RU RU2015130222A patent/RU2622105C2/ru active
- 2013-12-23 EP EP21194531.6A patent/EP3954688A1/en active Pending
- 2013-12-23 ES ES13864994T patent/ES2897496T3/es active Active
- 2013-12-23 BR BR112015014839-5A patent/BR112015014839B1/pt active IP Right Grant
- 2013-12-23 EP EP13864994.2A patent/EP2937348B1/en active Active
- 2013-12-23 CN CN201380066871.7A patent/CN105026391B/zh active Active
- 2013-12-23 WO PCT/CN2013/090252 patent/WO2014094664A1/zh active Application Filing
-
2015
- 2015-06-22 ZA ZA2015/04485A patent/ZA201504485B/en unknown
- 2015-06-22 IL IL239581A patent/IL239581B/en active IP Right Grant
-
2016
- 2016-01-15 HK HK16100440.8A patent/HK1212676A1/zh unknown
- 2016-05-03 HK HK16105012.5A patent/HK1217019A1/zh unknown
-
2017
- 2017-07-04 JP JP2017131078A patent/JP2017165787A/ja active Pending
-
2019
- 2019-02-05 JP JP2019018876A patent/JP2019065057A/ja active Pending
-
2020
- 2020-04-16 JP JP2020073415A patent/JP6986197B6/ja active Active
-
2021
- 2021-11-02 JP JP2021179425A patent/JP2022009922A/ja active Pending
-
2023
- 2023-11-17 JP JP2023195879A patent/JP2024009114A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP3965A (en) | Anthelminitic compounds and compositions and method of using thereof | |
ZA201303793B (en) | Substituted quinoline compounds and methods of use | |
DK3290415T3 (da) | Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme | |
EP2680697A4 (en) | PROCESS FOR PREPARING AN OREXINE RECEPTOR ANTAGONIST | |
EP2839286A4 (en) | COMPOUNDS AND METHOD FOR THE PRODUCTION OF CONJUGATE REAGENTS | |
EP2663565A4 (en) | HEZEROARYL COMPOUNDS AND METHOD FOR USE THEREOF | |
HRP20181704T1 (hr) | Kristalni oblik kidamida, metoda pripreme i uporabe istog | |
IL228072A0 (en) | Alkyl-substituted quinazoline compounds and methods of use | |
HK1216503A1 (zh) | 用於經皮傳遞安非他命的組合物及方法 | |
EP2847343A4 (en) | METHOD FOR PREPARING AN INTERMEDIATE FOR AN OREXIN RECEPTOR ANTAGONIST | |
HK1201532A1 (zh) | 美托咪定的製備方法 | |
IL239222A0 (en) | Processes for the preparation of 4-amino-3-halo-6- (converted) picolinates and 4-amino-5-fluoro-3-halo-6- (converted) picolinates | |
IL231505A0 (en) | Pharmaceutical preparation and method for its production | |
HK1217019A1 (zh) | 作爲鹽皮質激素受體拮抗劑的化合物的晶型及其製備方法 | |
EP2822557A4 (en) | PREPARATION AND USE OF HIMBACIN BICYCLIC DERIVATIVES AS RAP RECEPTOR ANTAGONISTS | |
EP2889303A4 (en) | CONNECTION OF A CRYSTAL FORM OF ANDROSTA-3B, 5A, 6B-TRIOL AND METHOD FOR THE PRODUCTION THEREOF | |
HK1210143A1 (zh) | 氮雜環丁烷酮化合物的晶型及其製備方法 | |
EP2814907A4 (en) | BORBASTLASTED LIQUID SCINTILLATE COMPOSITIONS AND METHOD OF MANUFACTURING THEREOF | |
HK1198647A1 (zh) | 八氫-環戊並 吡咯的製備方法 | |
IL238934A0 (en) | Methods for the preparation of phenyloxymethyl-nitro-imidazole derivatives and their use | |
EP2862571A4 (en) | CAMPTOTHECIN COMPOUND, AND ITS MANUFACTURE AND USE | |
ZA201209495B (en) | Novel methods for the preparation of p2x7r antagonists |